GeNO

Genova Diagnostics acquires Metametrix

Wednesday, July 11, 2012 09:17 AM

Genova Diagnostics, a global specialty clinical laboratory based in Asheville, N.C., has decided to acquire Metametrix, a clinical laboratory in Duluth, Ga.

More... »

GSK further extends HGS tender offer

Friday, June 29, 2012 02:14 PM

GlaxoSmithKline has extended its tender offer to acquire all of the outstanding shares of Human Genome Sciences for $13.00 per share in cash to 5:00 p.m. EST on July 20, 2012.

More... »

Merck Serono, Compugen establish new biomarker company Neviah Genomics

Monday, June 25, 2012 02:52 PM

Merck Serono of Darmstadt, Germany, and Compugen, a therapeutic product discovery company of Tel Aviv, Israel, have established a novel start-up company called Neviah Genomics, focused on the discovery and development of novel biomarkers for the prediction of drug-induced toxicity.

More... »

HGS sets July 16 deadline for acquisition proposals

Friday, June 15, 2012 02:09 PM

In connection with its ongoing strategic alternative review process, Human Genome Sciences (HGS) has set a bid date of July 16, 2012, for the submission of definitive proposals to acquire all outstanding common shares of HGS.

More... »

GSK extends tender offer for HGS shares

Monday, June 11, 2012 09:49 AM

GlaxoSmithKline has extended its tender offer to acquire all of the outstanding shares of Human Genome Sciences for $13.00 per share in cash to 5:00 p.m. EST on Friday, June 29, 2012. The tender offer was previously scheduled to expire at 12:00 midnight EST, at the end of the day on June 7, 2012.

More... »

Complete Genomics to restructure, cut 55 jobs

Wednesday, June 6, 2012 01:19 PM

Complete Genomics, a whole human genome sequencing company based in Mountain View, Calif., is taking steps to reduce cash consumption and has engaged Jefferies & Company to assist it in exploring strategic alternatives.

More... »

GSK’s Hart-Scott-Rodino waiting period expires for HGS tender offer

Monday, June 4, 2012 10:55 AM

GlaxoSmithKline’s waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended, expired as of June 1, 2012, giving GSK clearance to acquire all outstanding shares of Human Genome Sciences.

More... »

GSK offers $13 per share for HGS

Wednesday, May 9, 2012 11:46 PM

GlaxoSmithKline will not participate in Human Genome Sciences’ strategic alternatives review process and will instead commence a tender offer this week to acquire all outstanding shares of HGS for $13.00 per share in cash.

More... »

HGS refuses GSK unsolicited offer, considers alternatives

Friday, April 20, 2012 11:21 AM

Human Genome Sciences has refused GlaxoSmithKline’s unsolicited offer on April 11 proposing to acquire all of the outstanding shares of HGS for $13.00 per share in cash ($2.6 billion), an 81% premium to closing share price on April 18.

More... »

NY Genome Center receives $3 million grant, creates 500 jobs

Monday, April 9, 2012 12:20 PM

The Alfred P. Sloan Foundation has given a $3 million grant to independent non-profit New York Genome Center (NYGC) to help build the infrastructure needed to support a large-scale genome sequencing and bioinformatics facility for translational research.

More... »